Protective mechanism of action of the antifungal drug naftifine against Mycobacterium abscessus infection
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01105-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Jia Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Allylamine, Antifungal Agents, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Mycobacterium abscessus, a rapidly growing nontuberculous mycobacterium, causes chronic pulmonary infections that are difficult to treat due to extensive intrinsic drug resistance. Through high-content screening of 786 FDA-approved drugs against intracellular M. abscessus in human THP-1 macrophages, we identified naftifine, an antifungal allylamine, as a novel antimycobacterial agent with dual-acting therapeutic mechanisms. Naftifine demonstrated potent activity against reference strains and multidrug-resistant clinical isolates. It showed enhanced efficacy in intracellular environments compared to axenic culture, indicating significant host-directed effects. Mechanistic investigations revealed that naftifine operates through a unique dual mechanism. It directly targets bacteria by inhibiting MmpL3 (MAB_4508), the essential mycolic acid transporter, and modulates host immunity through autophagy activation via the mTOR pathway suppression. Whole-genome sequencing of spontaneous naftifine-resistant mutants identified point mutations (S302T and V299G) in MmpL3. Complementation studies confirmed MmpL3 as the primary molecular target. Cross-resistance analysis with other MmpL3 inhibitors (BM212 and AU1235) validated this target identification. Notably, naftifine represents the first MmpL3 inhibitor demonstrated to induce autophagy, distinguishing it from other MmpL3-targeting compounds. Naftifine-induced autophagy enhanced macrophage-mediated bacterial clearance and reduced infection-associated necrosis, improving host cell survival. In vivo studies demonstrated a significant reduction of pulmonary and splenic bacterial burden with reduced lung inflammation. Furthermore, naftifine exhibited synergistic activity with β-lactam antibiotics without antagonizing other clinically used antibiotics. This is the first report demonstrating the unique combination of MmpL3 inhibition and autophagy induction by a single compound against M. abscessus , establishing naftifine as a promising dual-action therapeutic candidate for treating multidrug-resistant infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
- Mycobacteria/Nocardia Laboratory, The University of Texas Health Science Center at Tyler, The University of Texas at Tyler School of Medicine, Tyler, Texas, USA.
ORCID-Profile: Jia Wang, Ashok K Chopra, Sunhee Lee
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Wang, J., Paroha, R., Sha, J., Verma, A. K., Neil, B. H., Kilgore, P. B., Hendrix, E. K., Brown-Elliott, B., Chopra, A. K., & Lee, S. (2026). Protective mechanism of action of the antifungal drug naftifine against Mycobacterium abscessus infection. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01105-25
Vancouver
Wang J, Paroha R, Sha J, Verma AK, Neil BH, Kilgore PB, et al. Protective mechanism of action of the antifungal drug naftifine against Mycobacterium abscessus infection. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01105-25
BibTeX
@article{Wang2026,
author = {Wang, Jia and Paroha, Ruchi and Sha, Jian and Verma, Atul K and Neil, Blake H and Kilgore, Paul B and Hendrix, Emily K and Brown-Elliott, Barbara and Chopra, Ashok K and Lee, Sunhee},
title = {Protective mechanism of action of the antifungal drug naftifine against Mycobacterium abscessus infection},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01105-25}
}
EUVIMED